Logo image of CANF

CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Fundamental Analysis

NYSEARCA:CANF - NYSE Arca - US13471N3008 - ADR - Currency: USD

1.19  -0.05 (-4.03%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CANF. CANF was compared to 568 industry peers in the Biotechnology industry. The financial health of CANF is average, but there are quite some concerns on its profitability. CANF is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CANF had negative earnings in the past year.
In the past year CANF has reported a negative cash flow from operations.
CANF had negative earnings in each of the past 5 years.
CANF had a negative operating cash flow in each of the past 5 years.
CANF Yearly Net Income VS EBIT VS OCF VS FCFCANF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

CANF has a worse Return On Assets (-128.91%) than 82.04% of its industry peers.
Looking at the Return On Equity, with a value of -307.95%, CANF is doing worse than 74.65% of the companies in the same industry.
Industry RankSector Rank
ROA -128.91%
ROE -307.95%
ROIC N/A
ROA(3y)-87.03%
ROA(5y)-114.94%
ROE(3y)-151.83%
ROE(5y)-244.41%
ROIC(3y)N/A
ROIC(5y)N/A
CANF Yearly ROA, ROE, ROICCANF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CANF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CANF Yearly Profit, Operating, Gross MarginsCANF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K -5K

More info and screens

5

2. Health

2.1 Basic Checks

CANF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CANF has been increased compared to 1 year ago.
CANF has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CANF Yearly Shares OutstandingCANF Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
CANF Yearly Total Debt VS Total AssetsCANF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

CANF has an Altman-Z score of -40.99. This is a bad value and indicates that CANF is not financially healthy and even has some risk of bankruptcy.
CANF has a worse Altman-Z score (-40.99) than 92.61% of its industry peers.
There is no outstanding debt for CANF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -40.99
ROIC/WACCN/A
WACC9.03%
CANF Yearly LT Debt VS Equity VS FCFCANF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 2.93 indicates that CANF has no problem at all paying its short term obligations.
CANF has a Current ratio of 2.93. This is in the lower half of the industry: CANF underperforms 66.02% of its industry peers.
A Quick Ratio of 2.93 indicates that CANF has no problem at all paying its short term obligations.
With a Quick ratio value of 2.93, CANF is not doing good in the industry: 64.08% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.93
CANF Yearly Current Assets VS Current LiabilitesCANF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.00% over the past year.
CANF shows a decrease in Revenue. In the last year, the revenue decreased by -8.27%.
The Revenue for CANF have been decreasing by -27.92% on average. This is quite bad
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.14%
Revenue 1Y (TTM)-8.27%
Revenue growth 3Y-0.88%
Revenue growth 5Y-27.92%
Sales Q2Q%-55.8%

3.2 Future

The Earnings Per Share is expected to grow by 31.34% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 2.69% on average over the next years.
EPS Next Y-1.01%
EPS Next 2Y6.34%
EPS Next 3Y31.34%
EPS Next 5YN/A
Revenue Next Year36.48%
Revenue Next 2Y16.83%
Revenue Next 3Y2.69%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CANF Yearly Revenue VS EstimatesCANF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1M 2M 3M
CANF Yearly EPS VS EstimatesCANF Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2023 2024 2025 2026 0 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CANF reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CANF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CANF Price Earnings VS Forward Price EarningsCANF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CANF Per share dataCANF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -500 -1K -1.5K

4.3 Compensation for Growth

A more expensive valuation may be justified as CANF's earnings are expected to grow with 31.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.34%
EPS Next 3Y31.34%

More info and screens

0

5. Dividend

5.1 Amount

CANF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAN FITE BIOPHARMA LTD-ADR

NYSEARCA:CANF (4/22/2025, 12:13:48 PM)

1.19

-0.05 (-4.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/bmo
Earnings (Next)08-28 2025-08-28
Inst OwnersN/A
Inst Owner Change9.95%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap5.94M
Analysts82.5
Price Target8.39 (605.04%)
Short Float %5.14%
Short Ratio2.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.57%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.99
P/FCF N/A
P/OCF N/A
P/B 2.4
P/tB 2.4
EV/EBITDA N/A
EPS(TTM)-2.19
EYN/A
EPS(NY)-1533.63
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS0.15
BVpS0.5
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -128.91%
ROE -307.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-87.03%
ROA(5y)-114.94%
ROE(3y)-151.83%
ROE(5y)-244.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50%
Cap/Sales 0.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.93
Quick Ratio 2.93
Altman-Z -40.99
F-Score4
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)52.06%
Cap/Depr(5y)78.86%
Cap/Sales(3y)0.89%
Cap/Sales(5y)1.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.14%
EPS Next Y-1.01%
EPS Next 2Y6.34%
EPS Next 3Y31.34%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.27%
Revenue growth 3Y-0.88%
Revenue growth 5Y-27.92%
Sales Q2Q%-55.8%
Revenue Next Year36.48%
Revenue Next 2Y16.83%
Revenue Next 3Y2.69%
Revenue Next 5YN/A
EBIT growth 1Y18.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.4%
OCF growth 3YN/A
OCF growth 5YN/A